Adrenocortical Carcinoma (ACC) Panel
Use
This test is designed for individuals who have a clinical or suspected diagnosis of hereditary adrenocortical carcinoma (ACC), as well as those with a personal or family history of ACC. It is also relevant for individuals with a history consistent with syndromes like Li-Fraumeni syndrome (LFS), familial adenomatous polyposis (FAP), multiple endocrine neoplasia type 1 (MEN1), or Lynch syndrome. Early and accurate diagnosis through this genetic testing can help guide management and treatment decisions.
Special Instructions
Testing is performed using the PGselect platform with NGS and CNV analysis. This test is New York State approved, and STAT testing is available, which adds a 25% surcharge if report delivery occurs after 16 days with blood sample submission.
Limitations
The test may have limitations in detecting certain genetic variants, particularly in regions of the genome that have complex structures or high homology. Variants that are present at low levels, below the detection threshold, may be missed. This test also does not include comprehensive coverage of all possible genetic variants associated with ACC, and incidental findings unrelated to ACC may not be reported.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided